Completed PHASE1 INTERVENTIONAL NCT00054106

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer

Sponsor: NCIC Clinical Trials Group

Conditions Prostate Cancer

Interventions buserelin conventional surgery custirsen sodium flutamide neoadjuvant therapy

Updated 8 times since 2017 Last updated: Aug 3, 2023 Started: Dec 10, 2002 Primary completion: Sep 23, 2004 Completion: Sep 22, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by NCIC Clinical Trials Group and has accumulated 8 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Sep 2023 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Apr 2020 — May 2020 [monthly]

Completed PHASE1
Jun 2018 — Apr 2020 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NCIC Clinical Trials Group

Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vancouver, Canada